[go: up one dir, main page]

King et al., 2000 - Google Patents

Tumour therapy using Salmonella

King et al., 2000

View PDF
Document ID
2974898410459306598
Author
King I
Luo X
Feng M
Ittensohn M
Li Z
Belcourt M
Lin S
Le T
Pike J
Troy K
Sznol M
Clairmont C
Bermudes D
Zheng L
Publication year
Publication venue
Emerging Drugs

External Links

Snippet

The development of novel therapies that are selective for cancer cells, with limited toxicity to normal tissues, has been a challenge for oncology researchers. Genetically modified Salmonella typhimurium, which is capable of multiplying selectively in tumours and …
Continue reading at www.academia.edu (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Micro-organisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0291—Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—PROCESSES USING MICRO-ORGANISMS
    • C12R1/00—Processes using micro-organisms
    • C12R1/01—Processes using micro-organisms using bacteria or actinomycetales
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Micro-organisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving micro-organisms or compositions thereof; Processes of preparing or isolating a composition containing a micro-organism; Culture media therefor

Similar Documents

Publication Publication Date Title
Pawelek et al. Bacteria as tumour-targeting vectors
Shen et al. Antitumor effect of VNP20009, an attenuated Salmonella, in murine tumor models
US9598697B2 (en) Recombinant bacterium to decrease tumor growth
Pawelek et al. Tumor-targeted Salmonella as a novel anticancer vector
Bcrmudcs et al. Tumor amplified protein expression therapy: Salmonella as a tumor-selective protein delivery vector
EP1012232B1 (en) Genetically modified tumor-targeted bacteria with reduced virulence
Ryan et al. Use of bacteria in anti‐cancer therapies
US8916372B2 (en) Strain of Salmonella enterica s. typhimurium, its use and a method to obtain a therapeutic vaccine vector
US5855880A (en) Avirulent microbes and uses therefor
JP4583607B2 (en) Attenuated microorganisms for the treatment of infectious diseases
Rius-Rocabert et al. Oncolytic bacteria: past, present and future
US20230090746A1 (en) Attenuated salmonella synthesizing antigens for vaccinating against helicobacter pylori
Chabalgoity et al. Live bacteria as the basis for immunotherapies against cancer
Dosoky et al. Engineering the gut microbiota to treat chronic diseases
EP0556333B1 (en) Avirulent salmonella microbes comprising a mutation in the cdt gene and uses therefor
MX2007006552A (en) Electroporation of mycobacterium and overexpression of antigens in mycobacteria.
King et al. Tumour therapy using Salmonella
JP5871617B2 (en) Lactic acid bacteria mutated to obligate anaerobic, method for producing the same, and expression vector that functions in obligate anaerobic lactic acid bacteria
Saltzman et al. Patterns of hepatic and splenic colonization by an attenuated strain of Salmonella typhimurium containing the gene for human interleukin-2: a novel anti-tumor agent
Feltis et al. Liver and circulating NK1. 1+ CD3− cells are increased in infection with attenuated Salmonella typhimurium and are associated with reduced tumor in murine liver cancer
Strahan et al. Impaired resistance to infection does not increase the virulence of Salmonella htrA live vaccines for mice
WO2022007741A1 (en) Genetically engineered live bacteria and methods of constructing the same
JP6802924B2 (en) Pegiocockspentosaseus strain for drug transmission for treating gastrointestinal diseases expressing and secreting cystatin and a pharmacological composition for preventing or treating gastrointestinal diseases containing the same.
EP0249449A1 (en) Bacterial strain for live vaccines
US20250000913A1 (en) Salmonella engineered for nontoxic colonization of tumors